Skip to main content
Erschienen in: Endocrine 3/2011

01.06.2011 | Original Article

Vertebral fractures in males with prolactinoma

verfasst von: Gherardo Mazziotti, Teresa Porcelli, Marilda Mormando, Ernesto De Menis, Antonio Bianchi, Carola Mejia, Tatiana Mancini, Laura De Marinis, Andrea Giustina

Erschienen in: Endocrine | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Data on osteoporotic fractures in hyperprolactinemia are limited. An increased prevalence of radiological vertebral fractures was recently observed in women with prolactin (PRL)-secreting adenoma, whereas it is unknown whether this observation may reflect a more general increased risk of fractures in this disease and whether the prevalence of fractures in males is affected by gonadal status. Thirty-two males (median age 47 years, range: 22–79) with PRL-secreting pituitary adenoma (10 with microadenoma and 22 with macroadenoma) and 64 control males, with normal PRL values and with comparable age to patients with hyperprolactinemia, were evaluated for vertebral fractures by a morphometric approach and for bone mineral density (BMD) by a dual-energy X-ray absorptiometry at lumbar spine. Vertebral fractures were shown in 12 patients with PRL-secreting adenoma (37.5%) and in 5 controls (7.8%, P < 0.001). Fractured patients had lower BMD T-score (P = 0.007) and longer duration of disease (P < 0.001) as compared to patients who did not fracture. Fractures occurred more frequently (P = 0.03) in patients with untreated hyperprolactinemia versus patients treated with cabergoline whose frequency of vertebral fractures was still higher than control subjects. The prevalence of vertebral fractures was not significantly different between eugonadal and hypogonadal patients (33.3% vs. 38.5%; P = 0.8). Moreover, no significant (P = 0.4) difference in serum testosterone values was found between fractured and not fractured males. Hyperprolactinemia is associated with high prevalence of radiological vertebral fractures in men with PRL-secreting adenoma. These findings would also suggest that PRL excess may produce negative skeletal effects independently of hypogonadism.
Literatur
1.
Zurück zum Zitat F.F. Casanueva, M.E. Molitch, J.A. Schlechte, R. Abs, V. Bonert, M.D. Bronstein, T. Brue, P. Cappabianca, A. Colao, R. Fahlbusch, H. Fideleff, M. Hadani, P. Kelly, D. Kleinberg, E. Laws, J. Marek, M. Scanlon, L.G. Sobrinho, J.A. Wass, A. Giustina, Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. 65, 265–273 (2006)CrossRef F.F. Casanueva, M.E. Molitch, J.A. Schlechte, R. Abs, V. Bonert, M.D. Bronstein, T. Brue, P. Cappabianca, A. Colao, R. Fahlbusch, H. Fideleff, M. Hadani, P. Kelly, D. Kleinberg, E. Laws, J. Marek, M. Scanlon, L.G. Sobrinho, J.A. Wass, A. Giustina, Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. 65, 265–273 (2006)CrossRef
2.
Zurück zum Zitat A. Fernandez, N. Karavitaki, J.A. Wass, Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. 72, 377–382 (2010)CrossRef A. Fernandez, N. Karavitaki, J.A. Wass, Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. 72, 377–382 (2010)CrossRef
3.
Zurück zum Zitat T. Mancini, F.F. Casanueva, A. Giustina, Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. North Am. 37, 67–99 (2008)PubMedCrossRef T. Mancini, F.F. Casanueva, A. Giustina, Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. North Am. 37, 67–99 (2008)PubMedCrossRef
4.
Zurück zum Zitat S.L. Greenspan, R.M. Neer, E.C. Ridgway, A. Klibanski, Osteoporosis in men with hyperprolactinemic hypogonadism. Ann. Intern. Med. 104, 777–782 (1986)PubMed S.L. Greenspan, R.M. Neer, E.C. Ridgway, A. Klibanski, Osteoporosis in men with hyperprolactinemic hypogonadism. Ann. Intern. Med. 104, 777–782 (1986)PubMed
5.
Zurück zum Zitat S.L. Greenspan, D.S. Oppenheim, A. Klibanski, Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann. Intern. Med. 110, 526–531 (1989)PubMed S.L. Greenspan, D.S. Oppenheim, A. Klibanski, Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann. Intern. Med. 110, 526–531 (1989)PubMed
6.
Zurück zum Zitat A. Shibli-Rahhal, J. Schlechte, The effects of hyperprolactinemia on bone and fat. Pituitary 12, 96–104 (2009)PubMedCrossRef A. Shibli-Rahhal, J. Schlechte, The effects of hyperprolactinemia on bone and fat. Pituitary 12, 96–104 (2009)PubMedCrossRef
7.
Zurück zum Zitat P. Vestergaard, J.O. Jørgensen, C. Hagen, H.C. Hoeck, P. Laurberg, L. Rejnmark, K. Brixen, J. Weeke, M. Andersen, F.L. Conceicao, T.L. Nielsen, L. Mosekilde, Fracture risk is increased in patients with GH deficiency or untreated prolactinomas—a case-control study. Clin. Endocrinol. 56, 159–167 (2002)CrossRef P. Vestergaard, J.O. Jørgensen, C. Hagen, H.C. Hoeck, P. Laurberg, L. Rejnmark, K. Brixen, J. Weeke, M. Andersen, F.L. Conceicao, T.L. Nielsen, L. Mosekilde, Fracture risk is increased in patients with GH deficiency or untreated prolactinomas—a case-control study. Clin. Endocrinol. 56, 159–167 (2002)CrossRef
8.
Zurück zum Zitat G. Mazziotti, T. Mancini, M. Mormando, E. De Menis, A. Bianchi, M. Doga, T. Porcelli, P.P. Vescovi, L. De Marinis, A. Giustina, High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary. (2011). [Epub ahead of print] PubMed PMID: 21301967 G. Mazziotti, T. Mancini, M. Mormando, E. De Menis, A. Bianchi, M. Doga, T. Porcelli, P.P. Vescovi, L. De Marinis, A. Giustina, High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary. (2011). [Epub ahead of print] PubMed PMID: 21301967
9.
Zurück zum Zitat G. Mazziotti, E. Canalis, A. Giustina, Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 123, 877–884 (2010)PubMedCrossRef G. Mazziotti, E. Canalis, A. Giustina, Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 123, 877–884 (2010)PubMedCrossRef
10.
Zurück zum Zitat J.A. Kanis, E.V. McCloskey, H. Johansson, O. Strom, F. Borgstrom, A. Oden, National osteoporosis guideline group: case finding for the management of osteoporosis with FRAX–assessment and intervention thresholds for the UK. Osteoporos. Int. 19, 1395–1408 (2008)PubMedCrossRef J.A. Kanis, E.V. McCloskey, H. Johansson, O. Strom, F. Borgstrom, A. Oden, National osteoporosis guideline group: case finding for the management of osteoporosis with FRAX–assessment and intervention thresholds for the UK. Osteoporos. Int. 19, 1395–1408 (2008)PubMedCrossRef
11.
Zurück zum Zitat J.A. Kanis, N. Burlet, C. Cooper, P.D. Delmas, J.Y. Reginster, F. Borgstrom, R. Rizzoli, European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO): European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 19, 399–428 (2008)PubMedCrossRef J.A. Kanis, N. Burlet, C. Cooper, P.D. Delmas, J.Y. Reginster, F. Borgstrom, R. Rizzoli, European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO): European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 19, 399–428 (2008)PubMedCrossRef
12.
Zurück zum Zitat H.K. Genant, M. Jergas, L. Palermo, M. Nevitt, R.S. Valentin, D. Black, S.R. Cummings, Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in the osteoporosis. The Study of Osteoporotic Fractures Research Group. J. Bone Miner. Res. 11, 984–996 (1996)PubMedCrossRef H.K. Genant, M. Jergas, L. Palermo, M. Nevitt, R.S. Valentin, D. Black, S.R. Cummings, Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in the osteoporosis. The Study of Osteoporotic Fractures Research Group. J. Bone Miner. Res. 11, 984–996 (1996)PubMedCrossRef
13.
Zurück zum Zitat M.C. Nevitt, B. Black, D.M. Black, K. Stone, S.A. Jamal, K. Ensrud, M. Segal, H.K. Genant, S.R. Cummings, The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann. Intern. Med. 128, 793–800 (1998)PubMed M.C. Nevitt, B. Black, D.M. Black, K. Stone, S.A. Jamal, K. Ensrud, M. Segal, H.K. Genant, S.R. Cummings, The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann. Intern. Med. 128, 793–800 (1998)PubMed
14.
Zurück zum Zitat T. Jalava, S. Sarna, L. Pylkkänen, B. Mawer, J.A. Kanis, P. Selby, M. Davies, J. Adams, R.M. Francis, J. Robinson, E. McCloskey, Association between vertebral fracture and increased mortality in osteoporotic patients. J. Bone Miner. Res. 18, 1254–1260 (2003)PubMedCrossRef T. Jalava, S. Sarna, L. Pylkkänen, B. Mawer, J.A. Kanis, P. Selby, M. Davies, J. Adams, R.M. Francis, J. Robinson, E. McCloskey, Association between vertebral fracture and increased mortality in osteoporotic patients. J. Bone Miner. Res. 18, 1254–1260 (2003)PubMedCrossRef
15.
Zurück zum Zitat J.A. Schlechte, B. Sherman, R. Martin, Bone density in amenorrheic women with and without hyperprolactinemia. J. Clin. Endocrinol. Metab. 56, 1120–1123 (1983)PubMedCrossRef J.A. Schlechte, B. Sherman, R. Martin, Bone density in amenorrheic women with and without hyperprolactinemia. J. Clin. Endocrinol. Metab. 56, 1120–1123 (1983)PubMedCrossRef
16.
Zurück zum Zitat D. Coss, L. Yang, C.B. Kuo, X. Xu, R.A. Luben, A.M. Walker, Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am. J. Physiol. Endocrinol. Metab. 279, E1216–E1225 (2000)PubMed D. Coss, L. Yang, C.B. Kuo, X. Xu, R.A. Luben, A.M. Walker, Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am. J. Physiol. Endocrinol. Metab. 279, E1216–E1225 (2000)PubMed
17.
Zurück zum Zitat S. Lotinun, L. Limlomwongse, V. Sirikulchayanonta, N. Krishnamra, Bone calcium turnover, formation, and resorption in bromocriptine- and prolactin-treated lactating rats. Endocrine 20, 163–170 (2003)PubMedCrossRef S. Lotinun, L. Limlomwongse, V. Sirikulchayanonta, N. Krishnamra, Bone calcium turnover, formation, and resorption in bromocriptine- and prolactin-treated lactating rats. Endocrine 20, 163–170 (2003)PubMedCrossRef
18.
Zurück zum Zitat D. Seriwatanachai, N. Krishnamra, J.P. van Leeuwen, Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. J. Cell. Biochem. 107, 677–685 (2009)PubMedCrossRef D. Seriwatanachai, N. Krishnamra, J.P. van Leeuwen, Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. J. Cell. Biochem. 107, 677–685 (2009)PubMedCrossRef
19.
Zurück zum Zitat D. Seriwatanachai, N. Charoenphandhu, T. Suthiphongchai, N. Krishnamra, Prolactin decreases the expression ratio of receptor activator of nuclear factor kappaB ligand/osteoprotegerin in human fetal osteoblast cells. Cell Biol. Intern. 32, 1126–1135 (2008)CrossRef D. Seriwatanachai, N. Charoenphandhu, T. Suthiphongchai, N. Krishnamra, Prolactin decreases the expression ratio of receptor activator of nuclear factor kappaB ligand/osteoprotegerin in human fetal osteoblast cells. Cell Biol. Intern. 32, 1126–1135 (2008)CrossRef
20.
Zurück zum Zitat D. Seriwatanachai, K. Thongchote, N. Charoenphandhu, J. Pandaranandaka, K. Tudpor, J. Teerapornpuntakit, T. Suthiphongchai, N. Krishnamra, Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone. 42, 535–546 (2008)PubMedCrossRef D. Seriwatanachai, K. Thongchote, N. Charoenphandhu, J. Pandaranandaka, K. Tudpor, J. Teerapornpuntakit, T. Suthiphongchai, N. Krishnamra, Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone. 42, 535–546 (2008)PubMedCrossRef
21.
Zurück zum Zitat S.C. Schuit, M. van der Klift, A.E. Weel, C.E. de Laet, H. Burger, E. Seeman, A. Hofman, A.G. Uitterlinden, J.P. van Leeuwen, H.A. Pols, Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34, 195–202 (2004)PubMedCrossRef S.C. Schuit, M. van der Klift, A.E. Weel, C.E. de Laet, H. Burger, E. Seeman, A. Hofman, A.G. Uitterlinden, J.P. van Leeuwen, H.A. Pols, Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34, 195–202 (2004)PubMedCrossRef
22.
Zurück zum Zitat G. Mazziotti, A. Angeli, J.P. Bilezikian, E. Canalis, A. Giustina, Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 17, 144–149 (2006)PubMedCrossRef G. Mazziotti, A. Angeli, J.P. Bilezikian, E. Canalis, A. Giustina, Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 17, 144–149 (2006)PubMedCrossRef
23.
Zurück zum Zitat P. Vestergaard, Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes–a meta-analysis. Osteoporos. Int. 18, 427–444 (2007)PubMedCrossRef P. Vestergaard, Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes–a meta-analysis. Osteoporos. Int. 18, 427–444 (2007)PubMedCrossRef
24.
Zurück zum Zitat T. Mancini, G. Mazziotti, M. Doga, R. Carpinteri, N. Simetovic, P.P. Vescovi, A. Giustina, Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone. 45, 784–788 (2009)PubMedCrossRef T. Mancini, G. Mazziotti, M. Doga, R. Carpinteri, N. Simetovic, P.P. Vescovi, A. Giustina, Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone. 45, 784–788 (2009)PubMedCrossRef
25.
Zurück zum Zitat G. Mazziotti, A. Bianchi, S. Bonadonna, V. Cimino, I. Patelli, A. Fusco, A. Pontecorvi, L. De Marinis, A. Giustina, Prevalence of vertebral fractures in men with acromegaly. J. Clin. Endocrinol. Metab. 93, 4649–4655 (2008)PubMedCrossRef G. Mazziotti, A. Bianchi, S. Bonadonna, V. Cimino, I. Patelli, A. Fusco, A. Pontecorvi, L. De Marinis, A. Giustina, Prevalence of vertebral fractures in men with acromegaly. J. Clin. Endocrinol. Metab. 93, 4649–4655 (2008)PubMedCrossRef
26.
Zurück zum Zitat G. Mazziotti, T. Porcelli, I. Patelli, P.P. Vescovi, A. Giustina, Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density. Bone 46, 747–751 (2010)PubMedCrossRef G. Mazziotti, T. Porcelli, I. Patelli, P.P. Vescovi, A. Giustina, Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density. Bone 46, 747–751 (2010)PubMedCrossRef
27.
Zurück zum Zitat E. Canalis, A. Giustina, J.P. Bilezikian, Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 357, 905–916 (2007)PubMedCrossRef E. Canalis, A. Giustina, J.P. Bilezikian, Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 357, 905–916 (2007)PubMedCrossRef
28.
Zurück zum Zitat G. Iván, N. Szigeti-Csúcs, M. Oláh, G.M. Nagy, M.I. Góth, Treatment of pituitary tumors: dopamine agonists. Endocrine. 28, 101–110 (2005)PubMedCrossRef G. Iván, N. Szigeti-Csúcs, M. Oláh, G.M. Nagy, M.I. Góth, Treatment of pituitary tumors: dopamine agonists. Endocrine. 28, 101–110 (2005)PubMedCrossRef
29.
Zurück zum Zitat C. Di Somma, A. Colao, A. Di Sarno, M. Klain, M.L. Landi, G. Facciolli, R. Pivonello, N. Panza, M. Salvatore, G. Lombardi, Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J. Clin. Endocrinol. Metab. 83, 807–813 (1998)PubMedCrossRef C. Di Somma, A. Colao, A. Di Sarno, M. Klain, M.L. Landi, G. Facciolli, R. Pivonello, N. Panza, M. Salvatore, G. Lombardi, Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J. Clin. Endocrinol. Metab. 83, 807–813 (1998)PubMedCrossRef
30.
Zurück zum Zitat A. Colao, C. Di Somma, S. Loche, A. Di Sarno, M. Klain, R. Pivonello, M. Pietrosante, M. Salvatore, G. Lombardi, Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin. Endocrinol. 52, 319–327 (2000)CrossRef A. Colao, C. Di Somma, S. Loche, A. Di Sarno, M. Klain, R. Pivonello, M. Pietrosante, M. Salvatore, G. Lombardi, Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin. Endocrinol. 52, 319–327 (2000)CrossRef
31.
Zurück zum Zitat A. Giustina, R. Lorusso, V. Borghetti, G. Bugari, V. Misitano, O. Alfieri, Impaired spontaneous growth hormone secretion in severe dialated cardiomyopathy. Am. Heart J. 131, 620–622 (1996)PubMedCrossRef A. Giustina, R. Lorusso, V. Borghetti, G. Bugari, V. Misitano, O. Alfieri, Impaired spontaneous growth hormone secretion in severe dialated cardiomyopathy. Am. Heart J. 131, 620–622 (1996)PubMedCrossRef
32.
Zurück zum Zitat E. Ghigo, G. Aimaretti, E. Arvat, F. Camanni, Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults. Endocrine. 15, 29–38 (2001)PubMedCrossRef E. Ghigo, G. Aimaretti, E. Arvat, F. Camanni, Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults. Endocrine. 15, 29–38 (2001)PubMedCrossRef
33.
Zurück zum Zitat M. Doga, S. Bonadonna, M. Gola, S.B. Solerte, G. Amato, C. Carella, A. Giustina, Current guidelines for adult GH replacement. Rev. Endocr. Metab. Disord. 6, 63–70 (2005)PubMedCrossRef M. Doga, S. Bonadonna, M. Gola, S.B. Solerte, G. Amato, C. Carella, A. Giustina, Current guidelines for adult GH replacement. Rev. Endocr. Metab. Disord. 6, 63–70 (2005)PubMedCrossRef
34.
Zurück zum Zitat A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29, 535–559 (2008)PubMedCrossRef A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29, 535–559 (2008)PubMedCrossRef
35.
Zurück zum Zitat G. Mazziotti, A. Bianchi, S. Bonadonna, M. Nuzzo, V. Cimino, A. Fusco, L. De Marinis, A. Giustina, Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J. Bone Miner. Res. 21, 520–528 (2006)PubMedCrossRef G. Mazziotti, A. Bianchi, S. Bonadonna, M. Nuzzo, V. Cimino, A. Fusco, L. De Marinis, A. Giustina, Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J. Bone Miner. Res. 21, 520–528 (2006)PubMedCrossRef
36.
Zurück zum Zitat G. Mazziotti, A. Bianchi, V. Cimino, S. Bonadonna, P. Martini, A. Fusco, L. De Marinis, A. Giustina, Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency. Pituitary. 11, 55–61 (2008)PubMedCrossRef G. Mazziotti, A. Bianchi, V. Cimino, S. Bonadonna, P. Martini, A. Fusco, L. De Marinis, A. Giustina, Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency. Pituitary. 11, 55–61 (2008)PubMedCrossRef
Metadaten
Titel
Vertebral fractures in males with prolactinoma
verfasst von
Gherardo Mazziotti
Teresa Porcelli
Marilda Mormando
Ernesto De Menis
Antonio Bianchi
Carola Mejia
Tatiana Mancini
Laura De Marinis
Andrea Giustina
Publikationsdatum
01.06.2011
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2011
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-011-9462-5

Weitere Artikel der Ausgabe 3/2011

Endocrine 3/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.